---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-019606"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:54:39.866817+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics Phase 2 HIT trial: primary endpoint missed, thrombotic events reduced >25%

## Summary
- Platelet count recovery (primary endpoint) did not differ between CAD-1005 and placebo arms.
- Thrombotic events: >75% in placebo vs 50% in CAD-1005 group (>25% absolute reduction).
- End-of-Phase 2 meeting with FDA scheduled for March 2026 to discuss Phase 3 path.
- CAD-1005 is the only 12-LOX inhibitor in clinical development worldwide.
- Trial concluded December 2025 after program transfer from Veralox Therapeutics.

## SEC filing metadata
- accession: 0001213900-26-019606
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390026019606/0001213900-26-019606-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390026019606/ea0278072-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-019606
- JSON: https://secwatch.observer/filing/0001213900-26-019606.json
- Plain text: https://secwatch.observer/filing/0001213900-26-019606.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.